Eugia Pharma Specialities Limited
Registered Address: India (India)
5 Questions to Ask Eugia Pharma Specialities Limited Before Signing a Manufacturing Contract
Bring these exact questions to your discovery call with their QA Director or account rep before wiring a production deposit:
- Q1: On 2026-02-27, FDA cited 21 CFR 211.166(a)(2) (Finished Product Testing, Stability & Expiration Dating). Can your Quality Unit share the signed 15-day CAPA response and verification logs showing this gap is closed?
- Q2: On 2026-02-27, FDA cited 21 CFR 211.188(a) (Master Manufacturing & Batch Production Records (MMR/BPR)). Can your Quality Unit share the signed 15-day CAPA response and verification logs showing this gap is closed?
- Q3: Do you perform 100% FTIR/HPLC identity testing on incoming active ingredients in-house (21 CFR 111.75(a)(1)), or do you rely on vendor COAs?
- Q4: Will you sign our Quality Agreement Rider requiring 24-hour notification if an FDA investigator issues a Form 482 or Form 483 at FEI 3011960448?
- Q5: Can we review a redacted Master Manufacturing Record (MMR) and Batch Production Record (BPR) with dual-operator weight verification and yield reconciliation?
Cross-Database Regulatory & Inspection Timeline
Unified chronological history across FDA ORA Inspections, Form 483s, Warning Letters, Enforcement Recalls, and OASIS Import Refusals.
FDA Form 483 issued to Eugia Pharma Specialities Limited (FEI 3011960448) on 2026-02-27 following an inspection of its sterile pharmaceutical manufacturer operations in India. The report documents 2 inspection observations centered on Finished Product Testing, Stability & Expiration Dating, Master Manufacturing & Batch Production Records (MMR/BPR).
- 21 CFR 211.166(a)(2) (Finished Product Testing, Stability & Expiration Dating): Releasing finished batches without verifying strength/potency/microbiological specs, or placing an expiration/best-by date on labels without supporting real-time or accelerated stability data.
- 21 CFR 211.188(a) (Master Manufacturing & Batch Production Records (MMR/BPR)): Missing Master Manufacturing Records (MMRs) or incomplete Batch Production Records (BPRs) lacking exact component weights, lot numbers, yield reconciliation, or second-person verification.
FDA Form 483 issued to Eugia Pharma Specialities Limited (FEI 3011960448) on 2026-02-06 following an inspection of its sterile drug manufacturer operations in India. The report documents 5 inspection observations centered on Personnel GMP Training, Gowning & Hygienic Practices, Electronic Record Data Integrity (21 CFR Part 11) & Retention.
- 21 CFR 211.28(a) (Personnel GMP Training, Gowning & Hygienic Practices): Operators performing manufacturing or QA tasks without documented GMP/SOP training, or observed gowning/hygiene deviations in production rooms.
- 21 CFR 211.42(c)(10) (Electronic Record Data Integrity (21 CFR Part 11) & Retention): Uncontrolled spreadsheets, shared laboratory logins, missing audit trails, backdated entries, or failure to retain batch and distribution records for the statutory window. REPEAT OBSERVATION
- 21 CFR 211.130(a) (Electronic Record Data Integrity (21 CFR Part 11) & Retention): Uncontrolled spreadsheets, shared laboratory logins, missing audit trails, backdated entries, or failure to retain batch and distribution records for the statutory window.
- 21 CFR 211.180(b) (Incoming Ingredient Identity Testing & COA Qualification): Failure to perform at least one test to verify the identity of every incoming dietary ingredient or raw component before use, or relying on a supplier's Certificate of Analysis (COA) without first qualifying the supplier.
- 21 CFR 211.186(a) (Master Manufacturing & Batch Production Records (MMR/BPR)): Missing Master Manufacturing Records (MMRs) or incomplete Batch Production Records (BPRs) lacking exact component weights, lot numbers, yield reconciliation, or second-person verification.
FDA Form 483 issued to Eugia Pharma Specialities Limited (FEI 3011960448) on 2025-11-14 following an inspection of its sterile drug product manufacturer operations in India. The report documents 2 inspection observations centered on Cleaning Validation, Sanitation Logs & Pest Control, CAPA, Out-of-Specification (OOS) & Complaint Investigations.
- 21 CFR 211.94(c) (Cleaning Validation, Sanitation Logs & Pest Control): Incomplete equipment cleaning/sanitation logs, inadequate allergen or cross-contamination changeover validation, or gaps in facility pest exclusion.
- 21 CFR 211.180(f) (CAPA, Out-of-Specification (OOS) & Complaint Investigations): Failure to thoroughly investigate unexplained batch discrepancies, Out-of-Specification lab results, or consumer complaints/adverse events and document root-cause Corrective and Preventive Actions (CAPA).
Manufacturer Right-of-Reply & Free Match Correction
GUARDRAIL PROTECTEDTo ensure fairness and accuracy, facility owners may submit verified Form 483 closeout evidence, CAPA completion statements, or entity-resolution corrections free of charge. Sponsorship never alters an FDA Record Index score.
6-Subsystem cGMP Radar Breakdown
Sub-scores mapped across FDA's six core inspection subsystems.
Verified AAA/AA Co-Packers in This Sector
Compare or request quotes from top-rated contract manufacturers with clean FDA inspection histories:
Score Provenance Receipts
Every point in this facility's FDA Record Index (42/100) is backed by a linked government record (36-month half-life decay).
| Event | Date | Weight | Receipt |
|---|---|---|---|
| Inspection Outcome (VAI) | 2026-02-27 | -8.5 pts | INSP-483-3011960448-20260227 ↗ |
| Inspection Outcome (VAI) | 2026-02-06 | -8.4 pts | INSP-483-3008461619-20260206 ↗ |
| Inspection Outcome (VAI) | 2025-11-14 | -8.0 pts | INSP-483-3009883410-20251114 ↗ |
| Form 483 (2 observations, 0 repeat) | 2026-02-27 | -5.1 pts | 483-3011960448-20260227 ↗ |
| Form 483 (5 observations, 1 repeat) | 2026-02-06 | -15.2 pts | 483-3008461619-20260206 ↗ |
| Form 483 (2 observations, 0 repeat) | 2025-11-14 | -4.8 pts | 483-3009883410-20251114 ↗ |